Current Report Filing (8-k)
July 13 2020 - 8:33AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event
reported)
July 13, 2020
electroCore, Inc.
(Exact name of registrant as specified
in its charter)
|
Delaware
|
|
001-38538
|
|
20-3454976
|
|
(State or other jurisdiction
of
incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification Number)
|
150 Allen Road, Suite 201
Basking Ridge, NJ 07920
(Address of principal executive offices
and zip code)
(973) 290-0097
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, Par Value $0.001 Per Share
|
ECOR
|
NASDAQ Global Select Stock Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 8.01. Other Events.
On July 13, 2020, electroCore, Inc. (the “Company”)
issued a press release announcing that the U.S. Food and Drug Administration has issued an Emergency Use Authorization (“EUA”)
for use of gammaCore Sapphire™ non-invasive vagus nerve stimulation (nVNS) at home or in a healthcare setting to acutely
treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow,
and for whom approved drug therapies are not tolerated or provide insufficient symptom relief. A copy of the press release is filed
with this Form 8-K as Exhibit 99.1.
There can be no assurance as to what impact, if any, the EUA
for gammaCore Sapphire will have on the Company, its business, operations or financial condition.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
electroCore, Inc.
|
|
|
|
|
July 13, 2020
|
/s/ Brian Posner
|
|
|
Brian Posner
|
|
|
Chief Financial Officer
|
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Apr 2023 to Apr 2024
